title: Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder.
abstract: Ocular angiogenesis is an important pathologic character of several ocular diseases, such as retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration (AMD). Inhibition of ocular angiogenesis has great therapeutic value for treating these dieses. Here we show that lenalidomide, an anti-tumor drug, has great anti-angiogenic potential in ocular diseases. Lenalidomide inhibits retinal endothelial cell viability in normal and pathological condition, and inhibits VEGF-induced endothelial cell migration and tube formation in vitro. Moreover, lenalidomide inhibits ocular angiogenesis in vivo through the reduction of angiogenesis- and inflammation-related protein expression. Collectively, lenalidomide is a promising drug for treating ocular angiogenesis through its anti-proliferative and anti-inflammatory property.
authors.affiliation: Eye Hospital, Nanjing Medical University, Nanjing, China; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, China.
authors.forename: Ling-Feng
authors.initials: LF
authors.lastname: Dong
authors.affiliation: Eye Hospital, Nanjing Medical University, Nanjing, China; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Yao
authors.affiliation: Eye Hospital, Nanjing Medical University, Nanjing, China; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, China.
authors.forename: Xiao-Qun
authors.initials: XQ
authors.lastname: Wang
authors.affiliation: Eye Hospital, Nanjing Medical University, Nanjing, China; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, China.
authors.forename: Kun
authors.initials: K
authors.lastname: Shan
authors.affiliation: Eye Hospital, Nanjing Medical University, Nanjing, China; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Yang
authors.affiliation: Eye Hospital, Nanjing Medical University, Nanjing, China; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, China. Electronic address: yanbiao1982@hotmail.com.
authors.forename: Biao
authors.initials: B
authors.lastname: Yan
authors.affiliation: Eye Hospital, Nanjing Medical University, Nanjing, China; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, China. Electronic address: jiangqin710@126.com.
authors.forename: Qin
authors.initials: Q
authors.lastname: Jiang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002460:Cell Line; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000473:pathology; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000473:pathology; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D018836:Inflammation Mediators / Q000378:metabolism; D000077269:Lenalidomide; D008253:Macaca mulatta; D051379:Mice; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D012171:Retinal Vessels / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000494:pharmacology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D018836:Inflammation Mediators; D042461:Vascular Endothelial Growth Factor A; D013792:Thalidomide; D000077269:Lenalidomide
keywords: Anti-inflammatory; Anti-proliferative; Lenalidomide; Ocular angiogenesis